Sell4

Adaptive Biotechnologies Corp

ADPT

Total Value

$5.3M

Net $3.2M sold

Filing Date

Sep 18, 2026

2 transactions

Sales

$3.2M

2 transactions

Trade Summary

On Sep 16, 2026, LO FRANCIS, Chief People Officer, sold $5.3M of Adaptive Biotechnologies Corp (ADPT) across 2 transactions. The filing covers Common Stock and reflects net selling of $3.2M. Reported prices ranged from $3.99 to $28.57. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

ADPT daily price with the insider's sale marked at $28.06.

Sold near the 6-month high · the stock trades 2% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: LO FRANCIS
Role: Chief People Officer
Location: SEATTLE, WA

Filing Details

Filing Date: Sep 18, 2026
Transaction Date: Sep 16, 2026
Accession Number: 0001780660-26-000022
Form Type: 4
Net Trading Amount: -$3.2M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 16, 2026	Common Stock	53,091	$12.14	Exercise	$644.5K
Sep 16, 2026	Common Stock	13,398	$8.46	Exercise	$113.3K
Sep 16, 2026	Common Stock	15,629	$3.99	Exercise	$62.4K
Sep 16, 2026	Common Stock	23,442	$8.12	Exercise	$190.3K
Sep 16, 2026	Common Stock	107,537	$28.02	Sale	$3.0M
Sep 16, 2026	Common Stock	7,869	$28.57	Sale	$224.8K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Sep 16, 2026	ADPT derivative	53,091	$12.14	Exercise	$644.5K
Sep 16, 2026	ADPT derivative	13,398	$8.46	Exercise	$113.3K
Sep 16, 2026	ADPT derivative	15,629	$3.99	Exercise	$62.4K
Sep 16, 2026	ADPT derivative	23,442	$8.12	Exercise	$190.3K

Want live alerts when LO FRANCIS trades again?

Download Insider Trades to track ADPT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
(F2)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F3)The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(F4)The option is fully vested and exercisable.
(F5)The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(F6)The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(F7)The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LO FRANCIS

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

98109

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/16/2026		M⁽¹⁾		53,091	A	$12.14	283,804	D
Common Stock	09/16/2026		M⁽¹⁾		13,398	A	$8.46	297,202	D
Common Stock	09/16/2026		M⁽¹⁾		15,629	A	$3.99	312,831	D
Common Stock	09/16/2026		M⁽¹⁾		23,442	A	$8.12	336,273	D
Common Stock	09/16/2026		S⁽¹⁾		107,537	D	$28.02⁽²⁾	228,736	D
Common Stock	09/16/2026		S⁽¹⁾		7,869	D	$28.57⁽³⁾	220,867	D
Common Stock								2,500	I	By You Jin Lee (spouse)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$12.14	09/16/2026		M⁽¹⁾			53,091	⁽⁴⁾	03/04/2032	Common Stock	53,091	$0	79,155	D
Stock Option (right to buy)	$8.46	09/16/2026		M⁽¹⁾			13,398	⁽⁵⁾	03/06/2033	Common Stock	13,398	$0	24,113	D
Stock Option (right to buy)	$3.99	09/16/2026		M⁽¹⁾			15,629	⁽⁶⁾	03/04/2034	Common Stock	15,629	$0	65,636	D
Stock Option (right to buy)	$8.12	09/16/2026		M⁽¹⁾			23,442	⁽⁷⁾	03/04/2035	Common Stock	23,442	$0	103,142	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The option is fully vested and exercisable.

5. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

6. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

7. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

	/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001780660-26-000022.

Adaptive Biotechnologies Corp

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when LO FRANCIS trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade